Evidence Intelligence™
- EvidenceScore™
- 74
- Moderate
- ImpactScore™
- 65
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Dulaglutide may improve weight loss in obese patients with diabetes
Last updated July 4, 2026
Key finding
The patient achieved a weight loss of 40 kg (−21%) over 6 months.
This study evaluated the effects of Dulaglutide on weight loss in a morbidly obese patient with type 2 diabetes, resulting in significant weight reduction and improved glycemic control.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Non-randomized CT
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of Dulaglutide on weight loss in a morbidly obese patient with type 2 diabetes, resulting in significant weight reduction and improved glycemic control.
Clinical relevance
This study highlights the potential of Dulaglutide as a therapeutic option for weight management in patients with type 2 diabetes, addressing a critical aspect of diabetes care. Effective weight loss can lead to improved health outcomes and reduced complications associated with obesity and diabetes.
Keep in mind
Single participant limits generalizability. Non-randomized design may introduce bias. No long-term follow-up data available.
Published in
Journal Reference
Publication details and source links for this paper.
Sohail B, Sahil B, Grishma S, et al. Dulaglutide for Weight Loss in a Morbidly Obese Patient with Type 2 Diabetes. Clinical Case Reports. 2024;12(9):e9403. doi:10.1002/ccr3.9403
Main Effects
Weight loss of 40 kg (−21%) over 6 months.
BMI decreased by 10.3 kg/m² over 6 months.
Daily caloric intake reduced from 6924 to 2538.9 calories.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dulaglutide and BMI, Body weight, Caloric intake, and 2 more.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
- BMI
- Body weight
- Caloric intake
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 64
2
Related topics
5
Evidence pairs
305
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Weight
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Mass Index
Save evidence
Evidence relationship
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 64
- Moderate
- ImpactScore™
- 73
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerGastrointestinal disorders incidence
Dulaglutide → Gastrointestinal disorders incidence
Dulaglutide → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- 64
- Moderate
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 53
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- 40 kg weight loss observed in 6 months.
- 10.3 kg/m² reduction in BMI recorded.
- Daily caloric intake decreased by 4385.1 calories.
Who this applies to
- Morbidly obese adults with type 2 diabetes.
- Patients seeking pharmacological weight loss options.
Keep in Mind
- Results are based on a single case study.
- Further research needed to confirm findings.
- Effectiveness in broader populations remains unclear.
Between the Lines
- Single participant limits generalizability.
- Non-randomized design may introduce bias.
- No long-term follow-up data available.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Mass Index, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- 74
- Moderate
- ImpactScore™
- 65
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 64
- Moderate
- ImpactScore™
- 73
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
3 studies
outcome_hubMeasures Body Mass Index as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
3 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Body Weight Evidence Hub
All studies measuring Body Weight
2 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Dulaglutide and BMI
Intervention: DulaglutideOutcome: BMI
3 results
All studies on Dulaglutide and Body weight
Intervention: DulaglutideOutcome: Body weight
2 results
All studies on Dulaglutide
Intervention: Dulaglutide
3 results
All studies measuring BMI
Outcome: BMI
3 results
All studies measuring Body weight
Outcome: Body weight
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 64.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Moderate | EvidenceScore™ 73.7 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect gastrointestinal adverse events?
Strong Evidence
GLP-1 Receptor Agonists may worsen Gastrointestinal Adverse Events or be associated with harm.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Moderate | EvidenceScore™ 64.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies and existing graph evidence signals.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve cgm time in range?
Moderate Evidence
GLP-1 Receptor Agonists may improve CGM Time in Range.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Time to glycemic target
EvidenceScore™ Emerging | EvidenceScore™ 52.5 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Switching to tirzepatide improves glycemic control and weight in type 2 diabetesGLP-1 agonists reduce heart fat thickness in diabetes.Higher dulaglutide doses improve weight loss in type 2 diabetesDietary supplements may lower diabetes risk in prediabetesDigital intervention improves glycemic control in type 2 diabetes patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.